Loading clinical trials...

Meibomian Gland Dysfunction Management | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGNA

Meibomian Gland Dysfunction Management

Meibomian Gland Dysfunction Management to Relieve Contact Lens Discomfort

NCT03652337•University of the Incarnate Word

Summary

The purpose of this study is to compare electronic debridement of the eyelid margin (BlephEx) to manual debridement of the eyelid margin as treatment options for patients intolerant to contact lens wear consequent to Meibomian gland dysfunction.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Habitual contact lens wearers whose contact lens wear time has reduced due to MGD will be preferentially considered for this study. Subjects who currently cannot wear contact lenses due to MGD may be considered on a case-by-case basis.

Exclusion Criteria

•Subjects who are currently using any prescription ophthalmic medications (such as antibiotics, steroids and immunomodulatory drugs) will be excluded from participation.
•Subjects who have active ocular infections will be excluded from participation.

Locations (1)

Rosenberg School of Optometry

San Antonio, Texas, United States

Key Dates

Start Date

May 10, 2018

Primary Completion Date

December 1, 2018

Completion Date

April 10, 2019

Last Updated

September 5, 2018

Enrollment

ESTIMATED participants

Conditions

Contact Lens DiscomfortMeibomian Gland Dysfunction

Interventions

BlephEx

DEVICE

Manual debridement

DEVICE

Therapeutic Efficacy and Safety of Non-Invasive RF Treatment in Refractory MGD

NCT06220474

Dry Eye SyndromesMeibomian Gland Dysfunction

View study

ENROLLING_BY_INVITATIONNA

Single Lipiflow Treatment to Reduce Pharmacologic Burden in DED

NCT06542276

MGD-Meibomian Gland Dysfunction

View study

ACTIVE_NOT_RECRUITINGNA

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 5, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Meibomian Gland Dysfunction Management

Inclusion Criteria

Exclusion Criteria

Therapeutic Efficacy and Safety of Non-Invasive RF Treatment in Refractory MGD

Single Lipiflow Treatment to Reduce Pharmacologic Burden in DED

Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD

Vectored Thermal Pulsation, Intense Pulsed Light, and Eyelid Warm Compress Therapies for MGD

Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction

Preoperative iLux on Cataract Surgery Derived Dry Eye Disease Due to Meibomian Gland Dysfunction